Methods and compositions for diagnosing, prognosing, and treating endometriosis
This document provides methods and materials related to genetic variations associated with endometriosis. For example, this document provides methods for using such genetic variations to assess risk of, or susceptibility of developing or diagnosing endometriosis.
1. A method of hybridizing a nucleic acid probe or synthesizing a nucleic acid product, comprising:
(a) hybridizing a nucleic acid probe to a polynucleic acid by nucleic acid hybridization or microarray analysis, wherein the polynucleic acid is from a sample from a human female subject with endometriosis, or
synthesizing a nucleic acid product from a polynucleic acid by PCR or sequencing, wherein the polynucleic acid is from a sample from a human female subject with endometriosis; and
(b) detecting a genetic variation in the polynucleic acid by the nucleic acid hybridization, microarray analysis, PCR or sequencing, wherein the genetic variation is:
a CNV with a sequence of SEQ ID NO:1, a CNV sub-region (SRN) with a sequence of SRN1-SRN3, or the complete complements thereof, wherein the genetic variation is of a TGFBR3 gene.
2. The method of claim 1 , wherein the genetic variation results in a loss of any one of the CNV or SRN.
3. The method of claim 1 , wherein the sample is from blood, saliva, urine, serum, tears, skin, tissue, or hair.
4. The method of claim 1 , wherein the sample comprises a purified nucleic acid or an amplified nucleic acid.
5. The method of claim 1 , wherein the microarray analysis is Comparative Genomic Hybridization (CGH) array analysis.
6. The method of claim 1 , wherein the microarray analysis is SNP microarray analysis.
7. The method of claim 1 , wherein the sequencing method is a high-throughput sequencing method.
8. The method of claim 1 , wherein the nucleic acid product synthesized from the polynucleic acid is cDNA.
9. The method of claim 1 , wherein the detecting comprises detecting a first genetic variation, wherein the first genetic variation is the CNV of the sequence of SEQ ID NO:1 or SRN1-SRN3, or the complete complements thereof, wherein the first genetic variation and a second genetic variation are in a panel comprising two or more genetic variations.
10. The method of claim 9 , wherein the second genetic variation is a CNV with a sequence of any one of SEQ ID NOs: 2-47, a CNV sub-region (SRN) with a sequence of any one of SRN4-SRN172, or a complete complement thereof.
11. The method of claim 1 , wherein the human female subject is asymptomatic or is infertile.
12. The method of claim 1 , wherein a whole genome or whole exome of the human female subject is analyzed.
13. The method of claim 1 , wherein the method further comprises generating a report indicating the human female subject has endometriosis.
14. The method of claim 10 , wherein the second genetic variation is a CNV with a sequence of any one of SEQ ID NO:18, 19, 22, 26, 30, or 32, a CNV sub-region (SRN) with a sequence of any one of SRN38, SRN39, SRN46, SRN50, SRN54, or SRN56 or a complete complement thereof.
15. The method of claim 1 , wherein the method further comprises administering to the human female subject that has endometriosis an amount of an agent effective to treat the endometriosis.
16. The method of claim 1 , wherein the TGFBR3 gene encodes any one of SEQ ID NOs:48-51.
17. The method of claim 9 , wherein detecting comprises detecting the first genetic variation and the second genetic variation.
18. The method of claim 9 , wherein the panel comprises 5 or more genetic variations.
19. The method of claim 9 , wherein the panel comprises 10 or more genetic variations.